Clinilabs is pleased to announce its partnership with InTandem Capital Partners, a leading healthcare-focused private equity firm, to support our growth as we drive to become the preeminent provider of CNS drug and device development services industry-wide. Gary Zammit, PhD, President & CEO of Clinilabs states, "I am pleased to announce that Clinilabs has partnered [...]
Clinilabs is pleased to announce “Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea” has recently been published in Sleep Medicine. This study focused on comorbid insomnia with obstructive sleep apnea (COMISA), highlighting its negative impact on daytime function and sleep quality. Clete A. Kushida M.D., Ph.D. [...]
Connect with us today to get the latest information on ongoing studies, research, press releases, and more.
Mike Detke, MD, PhD is a board-certified Psychiatrist, drug development scientist, and executive with over 25 years of research and leadership experience in the biotech and pharmaceutical sectors. Experienced across numerous CNS diseases and all phases of development, including many INDs and NDAs, he is a data-driven, high-integrity, transparent communicator and leader who always puts [...]
Rater training is crucial in clinical trials providing consistency and quality of subjective data collected from patients, caregivers, and clinicians, thereby ensuring the integrity of clinical trial endpoints and potentially leading to better clinical outcomes. Whereas poor management of rater training can have a detrimental effect on the entire study. Paul Michael Ramirez, PhD, is [...]
Clinilabs is excited to announce that Harald Murck, MD has joined our Scientific Advisory Board. Professor Harald Murck, MD, brings with him over 20 years of experience working with small biotech and large pharmaceutical companies. He has overseen and made significant contributions to the development of compounds in psychiatric indications and is considered an [...]
Join us as we celebrate our Scientific Advisory Board Member, Rashmi Patel, MD, PhD, in his new endeavors as Clinical Assistant Professor in the Department of Psychiatry at the University of Cambridge.
"Hyperarousal Features in the Sleep Architecture of Individuals with and without Insomnia," analyzed data from 1,710 individuals with insomnia and 1,455 individuals without insomnia. It found that individuals with insomnia showed signs of hyperarousal, including higher likelihood of waking from all sleep stages, increased relative alpha and theta power during certain sleep stages, decreased relative [...]
Eisai and Clinilabs Drug Development Corporation conducted an analysis of Lemborexant (LEM) to determine its effectiveness as a treatment for insomnia. LEM is a competitive dual orexin-receptor antagonist that has been approved in multiple countries for the treatment of insomnia in adults. The analysis found that LEM helps improve sleep duration, daytime functioning, and fatigue [...]
Gary Zammit, President and CEO of Clinilabs Drug Development Corporation, was at the ASCP conference in Miami Beach in May, where Dr. Zammit and the team at Eisai Inc. discussed the "Effect of Lemborexant on Sleep Architecture in Adults and Elderly Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease," presented on Poster #59.
